Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.
Description
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies | Oncogene
%0 Journal Article
%1 an2018epidermal
%A An, Zhenyi
%A Aksoy, Ozlem
%A Zheng, Tina
%A Fan, Qi-Wen
%A Weiss, William A.
%D 2018
%J Oncogene
%K EGFR EGFRvIII cancer-research fulltext
%N 12
%P 1561--1575
%R 10.1038/s41388-017-0045-7
%T Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
%U https://doi.org/10.1038/s41388-017-0045-7
%V 37
%X Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.
@article{an2018epidermal,
abstract = {Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.},
added-at = {2020-10-26T13:52:33.000+0100},
author = {An, Zhenyi and Aksoy, Ozlem and Zheng, Tina and Fan, Qi-Wen and Weiss, William A.},
biburl = {https://www.bibsonomy.org/bibtex/2c26bf67975cf9c7c7e21e4ab6b2cecdd/marcsaric},
description = {Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies | Oncogene},
doi = {10.1038/s41388-017-0045-7},
interhash = {5c275140e1fc0d7d360fe19ee9cc15d1},
intrahash = {c26bf67975cf9c7c7e21e4ab6b2cecdd},
issn = {14765594},
journal = {Oncogene},
keywords = {EGFR EGFRvIII cancer-research fulltext},
number = 12,
pages = {1561--1575},
refid = {An2018},
timestamp = {2020-10-26T13:52:33.000+0100},
title = {Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies},
url = {https://doi.org/10.1038/s41388-017-0045-7},
volume = 37,
year = 2018
}